Stealth BioTherapeutics Corp - ADR

NASDAQ:MITO   3:07:32 PM EDT
0.29
+0.01 (+2.65%)
Regulatory, Other Pre-Announcement

Stealth Biotherapeutics Granted Pre-NDA Meeting For Elamipretide As Potential Treatment For Barth Syndrome

Published: 06/14/2022 11:58 GMT
Stealth BioTherapeutics Corp - ADR (MITO) - Stealth Biotherapeutics Granted Pre-nda Meeting for Elamipretide As a Potential Treatment for Barth Syndrome.
Stealth Biotherapeutics Corp - Type B Meeting Scheduled With FDA Division of Cardiology and Nephrology.
Stealth Biotherapeutics Corp - Plans to Discuss New Clinical Data That May Inform a Potential NDA Submission.
Stealth Biotherapeutics Corp - Expects Type B Meeting to Occur During Q3.